METASTATIC SOLID TUMORS

This study tests a new drug called AVZO-1418 in people with advanced solid tumors that have spread. The main goals are to find a safe dose and see if the drug can shrink tumors. About 480 adults will take part in this first human trial.

This early-stage study tests a new drug called DS3610a in about 70 adults with advanced or metastatic solid tumors that have stopped responding to standard treatments. The main goal is to check the drug's safety and find the right dose. This is a first-in-human trial, so research…

This study tests a new drug called repotrectinib (TPX-0005) in people with advanced solid tumors that have certain genetic changes (ALK, ROS1, or NTRK). The goal is to see if the drug is safe and can shrink tumors. About 500 adults will take part, first to find the best dose, the…

This study tests a new treatment called EB-NK-301 for adults with advanced solid tumors that have stopped responding to standard therapies. EB-NK-301 uses specially engineered immune cells (CAR NK cells) to target a protein called TROP2 on cancer cells. The main goals are to chec…

This study tests a combination of experimental drugs (RAS(ON) inhibitors plus ivonescimab) in adults with advanced solid tumors that have a RAS mutation. The goal is to see if the combination is safe and can shrink or control tumors. About 370 participants whose cancer has worsen…

This study tests a new drug called AVZO-103 in people with advanced bladder cancer or other solid tumors that have spread. The drug is designed to attack cancer cells directly. The main goals are to check safety, find the best dose, and see if it shrinks tumors. About 355 adults …

This early-phase study tests a new cancer drug called ADCX-020 in 290 adults with advanced solid tumors that have not responded to standard treatments. The drug is an antibody drug conjugate designed to target and kill cancer cells. The study first finds the safest dose, then tes…

This early-stage study tests a new drug called ERAS-0015 in people with advanced solid tumors that have certain RAS mutations. The main goal is to see if the drug is safe and tolerable when given alone or with other treatments. About 200 adults will participate. This is not a cur…

This early-phase study tests a new experimental drug, RO7566802, alone or combined with another drug (atezolizumab) in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety and find the right dose. About 250 part…

This early-phase study tests a new drug called INCA33890 in about 408 adults whose solid tumors have spread or cannot be removed. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Participants must have tried other treatments first or be …

This early study tests a new treatment for people with stage 4 solid tumors that have stopped responding to standard care. Patients receive an injection of iron oxide nanoparticles, which travel to the tumor. A few hours later, a machine creates a magnetic field that heats the na…

This study tests a new drug called raludotatug deruxtecan (R-DXd) in people with advanced or metastatic solid tumors, including certain gynecological and genitourinary cancers. The goal is to see if the drug can shrink tumors or control the disease. About 200 adults who have alre…

This early-phase study tests a new drug called CKD-512, given alone or with pembrolizumab, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see early signs of tumor shrinkage. About 60…

This study tests a drug called repotrectinib in children and young adults (up to age 25) with advanced cancers that have specific genetic changes (ALK, ROS1, or NTRK). The first part finds the safest dose, and the second part checks if the drug shrinks tumors. About 75 participan…

This early-stage study tests a new drug, SLV-324, in about 70 adults whose solid tumors have spread and stopped responding to standard treatments. The main goal is to find a safe dose and see how the body handles the drug. Researchers will also watch for any signs that the drug i…

This early-phase study tests an experimental drug called MK-0472, given alone or with other cancer drugs (pembrolizumab or MK-1084), in people with advanced solid tumors that have spread. The main goals are to check safety, find the right dose, and see if the drug helps control t…

This early-stage trial tests a new drug called SKB107 in people with advanced solid tumors that have spread to the bone. The main goal is to check the drug's safety and how the body processes it. About 90 adults aged 18-75 who have tried other treatments without success may join.…

This early-phase study tests a new experimental drug called BGB-53038 in people with advanced or metastatic solid tumors that have a specific genetic change (KRAS mutation or amplification). The drug is a pan-KRAS inhibitor, meaning it aims to block many forms of the faulty KRAS …

This early-stage study tests a new drug called ERAS-4001 in people with advanced solid tumors that have certain KRAS mutations. The main goal is to see if the drug is safe and tolerable when given alone or with other treatments. About 200 participants will take part to help find …